Purpose: To evaluate the initial clinical experience of computed tomography (CT) imaging-guided percutaneous cryotherapy of bladder cancer. Patients and methods: This study was approved by the human subjects committee. Written informed consent was obtained from all patients. Thirty-two patients (22 males and 10 females; mean age, 62.7 years) with muscle-invasive bladder cancer were treated with CT imaging-guided percutaneous cryoablation. By using CT imaging system and local anesthesia in patients, a single or multiple 1.47 mm cryoprobes were used to freeze the target bladder tumor (mean tumor size, 2.8 cm; range, 1.3-4.5 cm) with a dual freeze-thaw cycle. Follow-up was performed to assess the clinical and technical outcome of patients treated with cryoablation for a minimum of 6 months (mean, 33 months; range, 6-48 months). Tumors were considered completely ablated if there was no evidence to suggest tumor enhancement at follow-up CT images. Results: Bladder cryoablation was clinically and technically successful in all 32 cases, 30 of which required only one treatment session. Bladder integrity was maintained in all patients. Major complications were not observed in any patient. Conclusion: Our initial experience of a minimally invasive method for ablating bladder tumors with CT imaging-guided percutaneous argon-helium cryoablation appears to be favorable, with acceptable operative and short-term clinical outcomes. The technique is safe and effective for the treatment of patients with muscle-invasive bladder cancer; however, long-term follow-up is needed.
Introduction
Bladder cancer is a relatively common malignant cancer in the urinary system, and shows an increasing tendency in Asia [15] . About 15 cases of bladder cancer occur per 100,000 persons worldwide and 0.13 million persons die of bladder cancer annually [23] . Although radical cystectomy and urinary diversion has been the gold standard of care for invasive bladder cancer, the technique is associated with significant morbidity and functional compromise [16] . Because of the perioperative morbidity and postoperative complications of radical cystectomy, many bladder-sparing options have been adopted for bladder cancer, including partial cystectomy, transurethral resection of bladder tumor (TURBT), chemotherapy, and/or radiation [9, 5] . Imaging-guided percutaneous ablative methods have been proposed as an alternative to partial tumor excision, such as partial nephrectomy [13] . Methods such as using computed tomography (CT)-or magnetic resonance imaging (MRI)-guided radiofrequency ablation and cryoablation can be performed percutaneously, and are likely to play an important role in the treatment of multiple tumors.
Cryoablation is a well-characterized and understood ablation technology that has been applied clinically to treat both benign and malignant disease in many different organs, such as the kidney, pancreas, prostate gland, adrenal gland, lung, and liver [8, 7, 4] . Argon-helium cryoablation is a new local ablation technique based on in situ freezing and devitalization of tissues. This technology caused some authors to question its use in cancers, with consideration of a theoretical risk of post-procedure hemorrhage [24] . However, there has some evidence to suggest that there is no significant difference in the rate of hemorrhage following radiofrequency ablation versus cryoablation [19] . Following the gradual downsizing of cryoprobes, percutaneous argon-helium cryoablation has been feasible, and offers several advantages versus other approaches. First, the ablation zone of the percutaneous cryoablation approach can be carefully monitored and visualised using CT or MRI. Second, the percutaneous approach is less invasive and relatively painless compared with other procedures, such as laparotomic methods and heat-based ablation modalities [14] .
A large body of evidence has suggested that imaging-guided percutaneous cryoablation is safe and effective for many cancers, such as liver tumors and renal tumors [20, 21, 25] . On the basis of the effectiveness and safety benefits of percutaneous cryoablation, and the advantages of CT in monitoring cancerous tissues effects of freezing, we treated patients' bladder tumors with CT imagingguided percutaneous argon-helium cryoablation. In this investigation, we document our experience of percutaneous cryoablation for bladder cancer in 32 patients. The goal of the current study was to examine the safety and efficacy of CT imaging-guided percutaneous argon-helium cryoablation of bladder cancer.
Patients and methods
A total of 32 patients with bladder cancer who were treated for bladder cancer at the Radiology Department, Xijing Hospital, Fourth Military Medical University between April 2003 and June 2010 were included in this study. Bladder cancer was diagnosed based on imaging findings and confirmed by cystoscopy. Clinical staging was based on the tumor-node-metastasis (TNM) classification; all patients in our study had clinical stage T2-T4aN0M0 bladder cancer. The 32 patients had a total of 34 tumors of 1.3-4.7 cm in diameter (mean size 2.8 cm). The clinical characteristics of the patients are summarized in Table 1 . All protocols in our study were approved by the Ethics Committee and the human subjects committee at Xijing Hospital. All patients participating in the study were Chinese in origin and provided written informed consent for the treatment.
In accordance with the protocol approved by the human subjects committee at Xijing Hospital, the criterion for the inclusion of patients in this study was that the subject was an adult with a metastatic neoplasm of the bladder, including advanced-stage bladder cancer, findings on CT that were interpreted as likely to represent a metastatic bladder tumor, and patients with recurrence after surgery. To be included in a study of an innovative therapy, patients should have correctable or normal hemostatic parameters and no contraindications to CT. The last criterion, but the most important, was that patients with a tumor of <5 cm in diameter were to receive cryoablation therapy in the study. Patients were ineligible for these protocols for several reasons [18] : distant spread of disease; hydronephrosis; use of other ablative therapies before cryoablation; a tumor of >5 cm in diameter; patient refusal to sign a consent form to approve the treatment; and patients with severe irritative bladder symptoms were not candidates for the bladder-preserving protocols.
Before the surgical procedure, we used the 18F flexible cystoscope working channel (CYF-2, Olympus Keymed, UK) to examine the location and number of tumors. Patients with larger tumors were examined by cystography. A preprocedural dual-source CT system (Somatom Definition, Siemens Medical Systems, Forchheim, Germany) was employed to assist in the planning of the CT-guided cryoablation treatment and to serve as the baseline with which postablation CT could be compared. An oral contrast agent in CT imaging was administrated for all patients with bladder cancer, and a three-cavity indwelling catheter was inserted in patients before surgery. Intraoperatively, an intravenous contrast agent for bladder was administered, and the bladder was irrigated with warm water. A catheter was inserted in patients 2-4 weeks after cryoablation. Percutaneous cryotherapy was performed using a cryoablation system (Cryo-hit, Galil Medical, Israel; employing argon/helium gases using 1.47 mm needles), including as many as 25 cryoprobes (Fig 1) . Interventional guidance and monitoring for cryotherapy were performed using a CT system scanner. All 32 patients underwent argon-helium cryoablation during a single procedure, expect for two who were re-treated. Procedures were performed after induction of local anesthesia in the patients. All 34 tumors were treated by an argon/helium gases-based Cryo-hit system and cryoprobes. According to the size and position of the tumor, a single or multiple 1.47 mm cryoprobes were used to freeze the target bladder tumor with a dual freeze-thaw cycle (10-min freeze, 5-min thaw) under CT guidance. In general, one cryoprobe generates an ice ball that is 3 cm in diameter and 5 cm in length along the probe shaft [3] .The iceball's dimensions were monitored via intraoperative CT. The rapid expansion of argon gas in a sealed cryoprobe with a distal uninsulated portion resulted in rapid freezing of tumor tissue, and cryoprobe tip temperatures reached a nadir of approximately À140°C within seconds. Thawing was accomplished by replacing the argon gas with helium gas. Tumor freezing was monitored; if the ice ball did not encompass the tumor entirely, additional cryoprobes were placed.
CT imaging was performed 24 h after cryoablation to document technical success, assessment of complications, such as bleeding or urinary fistula formation, and provide a baseline for future followup imaging and pretreatment CT. Follow-up images with CT were obtained at 3, 6, 12, 18, 24, 36 and 48 months after cryoablation. Tumors were considered completely ablated if there was no evidence to suggest tumor enhancement by intravenous contrast material [3] .
Results

Clinical data
Data for 32 patients are shown in Table 1 . All patients were from China. The images from CT and cystoscopic views revealed that all 32 patients suffered from muscle-invasive bladder cancer (clinical staging T2-T4aN0M0). There were 22 males and 10 females and their age ranged from 52 to 79 years. The mean tumor size on preoperative CT was 2.8 cm (range, 1.3-4.7) and there was no significant difference from the intraoperative measurement of 2.9 cm (range, 1.3-4.4). There has been some evidence to suggest that the cryoablation protocol is most efficacious for a tumor size of less than 4.0 cm [17] . Following the growth of our clinical experience, we were able to treat larger masses (tumor size did not exceed 5 cm). Therefore, in our study, the size of the tumors treated with cryoablation ranged from 1.3 to 4.7 cm.
Perioperative outcomes
Argon-helium cryoablation was successfully performed in all 32 patients. All tumors were completely ablated with a single procedure of cryoablation, except for two tumors that were ablated with two sessions of treatment. The first patient enrolled in the trial had small residual enhanced nodules at the periphery of the lesion, and the cyst was detected at 24 h after the cryoablation procedure. The patient's tumor, a 1.8 cm bladder cancer, showed residual enhancement in the portion that abutted the treated site and the patients was retreated by cryoablation. The other patient suffered a recurrence 6 months after cryoablation therapy. This patient initially had a 2.3 cm tumor mass, and was suspected to have a small residual hubble according to the image findings of the 3-month follow-up CT scan. Enhancement of the residual hubble was confirmed at the 6-month CT scan, and was retreated by cryoablation at 9 months after the initial treatment. Subsequently, CT images obtained for this patient at 3 and 6 months after the second treatment did not show any evidence of another recurrence. For small tumors, a single cryoprobe was used to ablate the tumor, whereas multiple cryoprobes were used to ablate the larger Fig. 1. (A) The computed tomography (CT) imaging-compatible argon-helium cryoablation system (Cryo-hit, Galil Medical, Israel; employing argon/helium gases using 1.47 mm needles). (B) CT imaging-compatible 1.47 mm diameter cryoprobe, which is able to form a 3.0 Â 5.0 cm iceball.
tumors. CT performed within 24 h after treatment showed that all tumors were completely ablated. A total of 29 of 32 patients had 33-month follow-up (range, 6-48 months) data that was adequate for analysis. The results indicated that there was no tumor recurrence or enhancement, except for the above two cases. Examples of the CT scans for the patients are shown in Fig. 2 . Complete resolution of the treated mass or a residual small cyst without enhancement was observed in CT for all patients during the follow-up period (Fig 3) , except for three patients who were lost to follow-up. There was no significant complications but no major complications associated with the cryoablation procedure. Symptoms of bladder cancer present before and within 3 days after percutaneous cryoablation are shown in Table 2 . All complications had disappeared completely after 2 weeks.
Discussion
Radical cystectomy and transurethral resection are currently the reference standards for treating muscle-invasive bladder cancer [6, 22] . A high recurrence rate is one of the main characteristics of transurethral resection, with some evidence to suggest a 76% repeated procedure rate at the original tumor site after transurethral resection [2] . Radical cystectomy is recommended as a curative treatment for advanced bladder cancer; however, more than half of these patients show distant metastasis as the predominant form of disease recurrence [11] . Although these therapeutic methods have achieved some positive effects, therapies for bladder cancer are far from satisfactory.
Argon-helium cryoablation, a new local ablative modality for the treatment of tumors, has been applied to various tumors, including hepatocellular carcinoma, renal carcinoma, prostate cancer, etc. There is a substantial body of evidence showing that percutaneous cryoablation treatment is very effective. In several studies, the local control rates of the treatment reached 83-95% on the basis of short-term follow-up [21] . In recent years, our group has successfully carried out percutaneous cryoablation treatment for different kinds of tumors, such as hepatocellular carcinoma, renal carcinoma, prostate cancer, renal angiomyolipoma, lung carcinoma, pelvic neoplasms, pancreatic carcinoma, adrenal neoplasm, and sacrum and ilium tumors. In the present study, our aim was to evaluate the efficacy and safety of CT imagingguided percutaneous argon-helium cryoablation of muscle-invasive bladder cancer. Thus, we performed local tumor cryoablation for 32 patients with muscle-invasive bladder cancer on the condition that the patients accepted the treatment. Our present data suggest that CT imaging-guided percutaneous argon-helium cryoablation of muscle-invasive bladder cancer is a successful technique. Follow-up CT was used as a measure of success by comparing this with the control images. Tumors in all 32 patients enrolled in the trial were ablated successfully by a single session, except the first two patients who received two sessions of cryoablation. Follow-up data indicated that all patients' tumors were completely resolved without enhancement, as observed by CT during the short-term imaging follow-up period, except for three patients who were lost to follow-up. Our previous results have suggested that most residual mass is detected in the early stage after ablation, typically within 3 months of cryoablation. This finding is consistent with the observation of a prior study, which showed that 70% of tumor recurrence is detected within 3 months [12] . Evidence shows that the incidence of recurrent tumor beyond 3 months is low, occurring at a rate of only 1% [1] . Thus, our short-term imaging follow-up data could indicate that all patients in our study were cured. Potential complications of bladder cryosurgery include post-thaw hemorrhage, vesical fistula formation, and uroclepsia. Vesical fistula and uroclepsia did not occur in any patient in our study, as confirmed by CT scanning. There was some evidence to suggest that bleeding from the probe tract was limited by using small probes, which are available with this argon gasbased system [10] . 1.47 mm cryoprobes were used for our study, and there was no significant bleeding in all patients but one, and the median blood loss of patients after treatment was approximately 185 mL. The hematocrit level of one patient was significantly reduced. They received a blood transfusion after the cryoablation treatment and their hematocrit level had returned to the baseline level after 1 week.
Conclusion
In our study, we have described our experience with a minimally invasive method for ablating bladder tumors for the first time. We have demonstrated that CT imaging-guided percutaneous cryotherapy is a very effective and safe technique for treating bladder cancer. CT imaging can be used to monitor preoperative, intraoperative, and postoperative tumors of patients, and to ensure that the tumor is completely ablated. Notably, this procedure can be accomplished with local anesthesia. Although percutaneous argon-helium cryoablation requires further assessment, the method shows promise.
